Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria

Journal of Medical Virology

Volumn 80, Issue 11, 2008, Pages 1972-1983

  Shen, Shuo ^a   Mahadevappa, Geetha ^a   Oh, Hsueh Ling Janice ^a   Boon, Yu Wee ^a   Choi, Yook Wah ^a   Hwang, Le Ann ^a   Seng, Gee Lim ^a   Hong, Wanjin ^a   Lal, Sunil K ^b   Tan, Yee Joo ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Baculovirus; HA5 pseudotyped lentiviral particles; Membrane fusion; Neutralizing antibodies

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS HEMAGGLUTININ;

AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS; CARBOXY TERMINAL SEQUENCE; INFLUENZA VIRUS A H5N1; INSECT CELL; MEMBRANE FUSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, VIRAL; BACTERIA; BACULOVIRIDAE; CELL LINE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; SPODOPTERA;

AVES; HEXAPODA; INFLUENZA A VIRUS;

EID: 54749150270     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21298     Document Type: Article

References (24)

1. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S, Yuen KY. 2005. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 353:1374-1385.
2. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
3. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG. 2005. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341:91-101.
4. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69:6705-6711.
5. Horimoto T, Kawaoka Y. 2006. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol Med 12:506-514.
6. Johansson BE, Brett IC. 2007. Changing perspective on immunization against influenza. Vaccine 25:3062-3065.
7. Katz JM, Lu X, Frace AM, Morken T, Zaki SR, Tumpey TM. 2000. Pathogenesis of and immunity to avian influenza A H5 viruses. Biomed Pharmacother 54:178-187.
8. Keng CT, Zhang A, Shen S, Lip KM, Fielding BC, Tan TH, Chou CF, Loh CB, Wang S, Fu J, Yang X, Lim SG, Hong W, Tan YJ. 2005. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents. J Virol 79:3289-3296.
9. Kilbourne ED. 1987. Influenza. New York: Plenum Publishing. pp. 164-165.
10. Kost TA, Condreay JP, Jarvis DL. 2005. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotech 23:567-575.
11. Lip KM, Shen S, Yang X, Keng CT, Zhang A, Oh HL, Li ZH, Hwang LA, Chou CF, Fielding BC, Tan TH, Mayrhofer J, Falkner FG, Fu J, Lim SG, Hong W, Tan YJ. 2006. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J Virol 80:941-950.
12. Lipatov AS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, Guan Y, Poon L, Webster RG. 2004. Influenza: Emergence and control. J Virol 78:8951-8959.
13. Lu L, Yu L, Kwang J. 2007. Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. Biochem Biophys Res Commun 358:404-409.
14. Nefkens I, Garcia JM, Ling CS, Lagarde N, Nicholls J, Tang DJ, Peiris M, Buchy P, Altmeyer R. 2007. Hemagglutinin pseudotyped lentiviral particles: Characterization of a new method for avian H5N1 influenza sero-diagnosis. J Clin Virol 39:27-33.
15. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus ADME, Fouchier RAM. 2006. Global patterns of influenza A virus in wild birds. Science 312:384-388.
16. Peiris JS, de Jong MD, Guan Y. 2007. Avian influenza virus (H5N1): A threat to human health. Clin Microbiol Rev 20:243-267.
17. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. 2006. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: A double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194:1394-1397.
18. Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 69:531-569.
19. Subbarao K, Luke C. 2007. H5N1 viruses and vaccines. PLoS Pathol 3:e40.
20. Tan YJ, Lim SP, Ting AE, Goh PY, Tan YH, Lim SG, Hong W. 2003. An anti-HIV-1 gp120 antibody expressed as an endocytotic transmembrane protein mediates internalization of HIV-1. Virology 315:80-92.
21. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battagalia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737.
22. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady C, Hay CM, Wolff M, She D, Cox MMJ. 2006. Dose-related safety and immunogenicity of a trivalent baculovirus expressed influenza virus hemagglutinin vaccine in elderly adults. J Infect Dis 193:1223-1228.
23. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M. 2007. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial. JAMA 297:1577-1582.
24. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MMJ. 2005. Expression and purification of an influenza hemagglutinin - One step closer to a recombinant protein-based influenza vaccine. Vaccine 24:2176-2185.